文献类型：期刊文献

英文题名：Reversing Anticancer Drug Resistance by Synergistic Combination of Chemotherapeutics and Membranolytic Antitumor β-Peptide Polymer

作者：Shao, Ning[1];Yuan, Ling[2];Liu, Longqiang[2];Cong, Zihao[2];Wang, Jiangzhou[2];Wu, Yueming[2];Liu, Runhui[1,2]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]East China Univ Sci & Technol, Shanghai Frontiers Sci Ctr Optogenet Tech Cell Met, Frontiers Sci Ctr Materiobiol & Dynam Chem, Key Lab Ultrafine Mat,Res Ctr Biomed Mat,Minist Ed, Shanghai 200237, Peoples R China

年份：2024

卷号：146

期号：16

起止页码：11254

外文期刊名：JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

收录：;EI(收录号：20241615920102);WOS:【SCI-EXPANDED(收录号:WOS:001201316400001)】；

基金：The authors also thank Research Center of Analysis and Test of East China University of Science and Technology for the help on the characterization. Thanks for the support of the Analysis and Testing Center of School of Chemical Engineering, East China university of Science and Technology. The authors thank the staff members of the Integrated Laser Microscopy System at the National Facility for Protein Science in Shanghai (NFPS), Zhangjiang Lab, China, for providing technical support and assistance in data collection and analysis.

语种：英文

外文关键词：Cancer cells - Cells - Chemotherapy - Diseases

摘要：Multidrug resistance is the main obstacle to cancer chemotherapy. Overexpression of drug efflux pumps causes excessive drug efflux from cancer cells, ultimately leading to drug resistance. Hereby, we raise an effective strategy to overcome multidrug resistance using a synergistic combination of membranolytic antitumor beta-peptide polymer and chemotherapy drugs. This membrane-active beta-peptide polymer promotes the transmembrane transport of chemotherapeutic drugs by increasing membrane permeability and enhances the activity of chemotherapy drugs against multidrug-resistant cancer cells. As a proof-of-concept demonstration, the synergistic combination of beta-peptide polymer and doxorubicin (DOX) is substantially more effective than DOX alone against drug-resistant cancer both in vitro and in vivo. Notably, the synergistic combination maintains a potent anticancer activity after continuous use. Collectively, this combination therapy using membrane lytic beta-peptide polymer appears to be an effective strategy to reverse anticancer drug resistance.